Anti-EGF-R (Human) mAb

WB - 1:1000-1:2000 IP - 2-5 uL/250 uL of cell extract from 5x106 cells FCM - 1:100 (final concentration) ICC - 1:100

The epidermal growth factor receptor (EGFR, ErbB-1) is a 170 kDa transmembrane glycoprotein that possesses intrinsic tyrosine kinase activity. There are several EGF family ligands including epidermal growth factor (EGF), amphiregulin (AR), heparin-binding epidermal growth factor (HB-EGF), epiregulin, betacellulin, transforming growth factor-α (TGF-α) and epigen, which can bind and activate the EGFR. Ligand binding facilitates dimerization of the EGFR, which activates downstream pathways known to be involved in cell growth, proliferation, differentiation and migration. Other members of the receptor tyrosine kinase family, which include EGFR, ErbB-2/HER-2, ErbB-3/HER-3 and ErbB-4/HER-4, are also known to play important roles in regulating a wide variety of cellular functions. Overexpression by gene amplification or mutation of these receptors correlates with the development and progression of several human cancers, as well as poor prognosis. Consequently, these receptors have been identified not only as a possible prognostic markers but also primarily a rational molecular target for an anticancer agents.

The protein concentration should be 1 mg/mL and the IgG concentration should be 100 ug/mL in PBS 50% glycerol, pH 7.2. No preservatives are contained.

Human: 1950 Mouse: 13645

Intracellular domain Recombinant human EGF-R (648-1186 aa)

This antibody reacts with human EGF-R on Western blotting, Immunoprecipitation and Immunocytochemistry and Flow cytometry. This antibody does not recognize human c-erbB2.

1 year

This antibody was concentrated from hybridoma (clone 6F1) supernatant. This hybridoma was established by fusion of mouse myeloma cell P3U1 with Balb/c mouse splenocyte immunized with the recombinant human EGF-R cytoplasmic region (648-1186 aa).

EGF